Lexaria Bioscience Completes CBD Hypertension Study, Receives Second Patent in Japan
Kelowna, British Columbia -- July 27, 2021 -- NewsGenie -- Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) has completed dosing in its second human clinical study of 2021, HYPER-H21-2, which involved 16 volunteers with pre- or mild hypertension receiving multiple doses of DehydraTECH™ 2.0-enabled CBD against a placebo. The study monitored blood pressure, heart rate, arterial stiffness, physical activity, and sleep quality over 24 hours to understand the effects of DehydraTECH 2.0-enabled CBD.
The company anticipates preliminary results in September or earlier. A prior study, HYPER-H21-1, used a single 300 mg dose of DehydraTECH 2.0-enabled CBD, and took blood samples from 24 volunteers every 10 minutes for 3 hours, evaluating blood pressure, heart rate and inflammatory markers associated with cardiovascular disease and biomarkers of nitric oxide. Preliminary blood pressure results from HYPER-H21-1 are expected soon, with further blood chemistry analysis to follow. Both studies were randomized, double-blinded, and fully funded by Lexaria.
Lexaria will commence HYPER-H21-3, its third hypertension study of 2021, following analysis of the results from both HYPER-H21-2 and HYPER-H21-1.
Lexaria also announced the allowance of its second patent in Japan for "Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof." This marks the 21st patent granted to Lexaria and the 17th in its first patent family. The patent covers the use of non-psychoactive cannabinoids, among other active ingredients.
Lexaria's DehydraTECH™ technology enhances the way active pharmaceutical ingredients enter the bloodstream, improving the effectiveness of fat-soluble active molecules. It has demonstrated increased bio-absorption, reduced onset time, and masked unwanted tastes in cannabinoids and nicotine. The technology is being evaluated for use with antiviral drugs, vitamins, and NSAIDs. Lexaria has licensed DehydraTECH to companies for smokeless nicotine products and cannabinoid beverages, edibles, and oral products. The company operates a licensed research laboratory and holds 21 granted patents with over 50 pending worldwide.
For further information, visit www.lexariabioscience.com.